+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07456605

Testing Safety and Optimal Dose of Liposomal Curcumin Infusion in Adults with Relapsed or Refractory Multiple Myeloma

Led by University Health Network, Toronto · Updated on 2026-06-12

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety of an investigational drug called Liposomal Curcumin LipoCurc in adults with relapsed or refractory multiple myeloma. The study seeks to find the highest dose that can be given without causing very severe side effects. Liposomal Curcumin contains curcumin, a natural substance from turmeric, which has shown antioxidant, anti-inflammatory, and anti-cancer properties in laboratory studies. The product is given by infusion to improve absorption compared to oral supplements. Participants receive increasing doses of LipoCurc starting at 350 mgm2, with later participants receiving higher doses up to 500 mgm2 if prior doses do not cause severe side effects. The study uses a sequential design to monitor safety closely and adjust dosing accordingly. The infusion is administered intravenously, and doses are escalated until a dose is found that causes severe but temporary side effects. No doses higher than this level will be given. During the study, participants are closely monitored for side effects, particularly serious blood-related events such as neutropenia, thrombocytopenia, anemia, and hemolysis, over a two-year period. Researchers measure response to treatment including partial response rates, progression-free survival, duration of response, and overall survival. Safety is tracked through adverse event reporting, laboratory tests, and clinical assessments. The total participation time can last up to two years with regular visits and evaluations to ensure participant safety and to assess the drugs effects.

CONDITIONS

Brief Title

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

Research Team

G

Guido Lancman, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here